Interactive science portfolio

MMV’s portfolio focuses on delivering efficacious medicines that are affordable, accessible and appropriate for use in malaria endemic areas. Specifically, the goal is to develop products that will provide: efficacy against drug-resistant strains of Plasmodium falciparum, potential for intermittent treatments (infants and pregnancy), safety in small children (less than 6 months old), safety in pregnancy, efficacy against Plasmodium vivax (including radical cure), efficacy against severe malaria, and transmission-blocking treatment.

The MMV project portfolio is updated quarterly. Click on a project below for more information.

• Download MMV's portfolio at end of 1st quarter, 2012 [360Kb]  
• Download the global malaria portfolio at end of 1st quarter, 2012. [360Kb] 
• Download the global malaria portfolio, classified by therapeutic type at end of 1st quarter, 2012 [515Kb]

For more information about the global malaria portfolio, read the article: The Global Portfolio of New Antimalarial Medicines Under Development.

MP - miniportfolio: MMV pioneered the miniportfolio model. The model assures flexibility in allocation of resources – established between MMV and a Pharmaceutical or Biotechnology partner – from one project to another. In this way, resources are utilized as efficiently as possible.